Portal’s Houston portfolio company CrossBridge Bio acquired by Eli Lilly!
Share
Portal’s Houston-based portfolio company focused on ADCs, CrossBridge Bio, was acquired by Eli Lilly in a deal worth up to $300 million! Congratulations to the CrossBridge Bio team!
Stay up-to-date on the latest VC, biotech, and med tech news in Chicago and across the U.S. Sign up with your email address below to get our monthly newsletter delivered to your inbox!